Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Alteration of cellular behavior and response to PI3K pathway inhibition by culture in 3D collagen gels.

Fallica B, Maffei JS, Villa S, Makin G, Zaman M.

PLoS One. 2012;7(10):e48024. doi: 10.1371/journal.pone.0048024. Epub 2012 Oct 23.

2.

Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.

Guenther MK, Graab U, Fulda S.

Cancer Lett. 2013 Sep 1;337(2):200-9. doi: 10.1016/j.canlet.2013.05.010. Epub 2013 May 16.

PMID:
23684925
3.

Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells.

Chen G, Chen SM, Wang X, Ding XF, Ding J, Meng LH.

J Biol Chem. 2012 Apr 6;287(15):12132-41. doi: 10.1074/jbc.M111.302299. Epub 2012 Feb 15. Erratum in: J Biol Chem. 2012 Jun 1;287(23):19336.

4.

Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells.

Bhattacharya B, Akram M, Balasubramanian I, Tam KK, Koh KX, Yee MQ, Soong R.

Cancer Biol Ther. 2012 Jan 1;13(1):34-42. doi: 10.4161/cbt.13.1.18437.

PMID:
22336586
5.

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment.

Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ.

Breast Cancer Res Treat. 2010 Jul;122(1):35-43. doi: 10.1007/s10549-009-0502-2. Epub 2009 Aug 22.

6.

Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo.

Segerström L, Baryawno N, Sveinbjörnsson B, Wickström M, Elfman L, Kogner P, Johnsen JI.

Int J Cancer. 2011 Dec 15;129(12):2958-65. doi: 10.1002/ijc.26268. Epub 2011 Aug 29.

7.

Toward single cell traction microscopy within 3D collagen matrices.

Hall MS, Long R, Feng X, Huang Y, Hui CY, Wu M.

Exp Cell Res. 2013 Oct 1;319(16):2396-408. doi: 10.1016/j.yexcr.2013.06.009. Epub 2013 Jun 25. Review.

8.

The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.

López-Fauqued M, Gil R, Grueso J, Hernandez-Losa J, Pujol A, Moliné T, Recio JA.

Int J Cancer. 2010 Apr 1;126(7):1549-61. doi: 10.1002/ijc.24926.

9.

Chloroquine overcomes resistance of lung carcinoma cells to the dual PI3K/mTOR inhibitor PI103 by lysosome-mediated apoptosis.

Enzenmüller S, Gonzalez P, Debatin KM, Fulda S.

Anticancer Drugs. 2013 Jan;24(1):14-9. doi: 10.1097/CAD.0b013e32835a36db.

PMID:
23111416
10.

Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo.

Werzowa J, Koehrer S, Strommer S, Cejka D, Fuereder T, Zebedin E, Wacheck V.

J Invest Dermatol. 2011 Feb;131(2):495-503. doi: 10.1038/jid.2010.327. Epub 2010 Nov 4.

11.

PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.

Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM.

Anticancer Res. 2010 Dec;30(12):4951-8.

12.

PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.

Shepherd C, Banerjee L, Cheung CW, Mansour MR, Jenkinson S, Gale RE, Khwaja A.

Leukemia. 2013 Mar;27(3):650-60. doi: 10.1038/leu.2012.285. Epub 2012 Oct 5.

PMID:
23038273
13.

Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies.

Gürsel DB, Connell-Albert YS, Tuskan RG, Anastassiadis T, Walrath JC, Hawes JJ, Amlin-Van Schaick JC, Reilly KM.

Neuro Oncol. 2011 Jun;13(6):610-21. doi: 10.1093/neuonc/nor035.

14.

Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.

Chiarini F, Falà F, Tazzari PL, Ricci F, Astolfi A, Pession A, Pagliaro P, McCubrey JA, Martelli AM.

Cancer Res. 2009 Apr 15;69(8):3520-8. doi: 10.1158/0008-5472.CAN-08-4884. Epub 2009 Apr 7.

15.

Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.

Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S.

Clin Cancer Res. 2011 Apr 15;17(8):2260-9. doi: 10.1158/1078-0432.CCR-10-1993. Epub 2011 Jan 10.

16.

Inhibition of phosphatidylinositol 3-kinase signaling in hepatic stellate cells blocks the progression of hepatic fibrosis.

Son G, Hines IN, Lindquist J, Schrum LW, Rippe RA.

Hepatology. 2009 Nov;50(5):1512-23. doi: 10.1002/hep.23186.

17.

Jolkinolide B induces apoptosis in MCF-7 cells through inhibition of the PI3K/Akt/mTOR signaling pathway.

Xu HY, Chen ZW, Hou JC, Du FX, Liu JC.

Oncol Rep. 2013 Jan;29(1):212-8. doi: 10.3892/or.2012.2113. Epub 2012 Oct 31.

PMID:
23129237
18.

Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.

Yuen HF, Abramczyk O, Montgomery G, Chan KK, Huang YH, Sasazuki T, Shirasawa S, Gopesh S, Chan KW, Fennell D, Janne P, El-Tanani M, Murray JT.

Biosci Rep. 2012 Aug;32(4):413-22. doi: 10.1042/BSR20120050.

19.

The XTT cell proliferation assay applied to cell layers embedded in three-dimensional matrix.

Huyck L, Ampe C, Van Troys M.

Assay Drug Dev Technol. 2012 Aug;10(4):382-92. doi: 10.1089/adt.2011.391. Epub 2012 May 10.

20.

Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.

Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, Lazar AJ, Pollock RE, Lev D.

Mol Cancer Ther. 2009 May;8(5):1157-68. doi: 10.1158/1535-7163.MCT-08-1008. Epub 2009 May 5.

Supplemental Content

Support Center